New Data on the Pharmacokinetic Profile of TEPEZZA™ (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
DUBLIN--(BUSINESS WIRE)--Horizon announces new TEPEZZA pharmacokinetic data and Thyroid Eye Disease (TED) data published in the Journal of the Endocrine Society.